Special Issue "Economics of New Drug Development and Approval"
A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601).
Deadline for manuscript submissions: closed (14 February 2014)
Dr. Joseph A. DiMasi
Economic Analysis, Tufts Center for the Study of Drug Development, Tufts Medical School, Tufts University, 75 Kneeland Street, Suite 1100, Boston, MA 02109, USA
Website | E-Mail
Interests: biopharmaceutical R&D costs; risks; and time; drug and biologics regulation; innovation incentives; economic structure of the biopharmaceutical industry
The development of new drugs is an important source of medical innovation. It is also exceptionally lengthy, risky, and costly. The economics of the pharmaceutical and biotechnology industries are driven, to a large extent, by these realities. That has led to numerous regulatory programs and policies designed with the hope that the regulatory approval process will be streamlined while maintaining review standards and also that the development of important new therapies will be facilitated. Industry, for its part, has experimented in recent years with reorganizing internal R&D activities and developing new models of interacting with academic medical centers, non-profit institutes, government agencies, and with each other. This issue welcomes articles on policies, programs, and processes that can affect incentives to develop new drugs and biologics, and generally on development, regulatory, promotional, and market processes that impact the economics of new drug development and approval.
Dr. Joseph A. DiMasi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pharmaceutical R&D processes
- drug regulatory approval policies
- incentives for pharmaceutical innovation
- metrics on new drug development and approval
- medical and economic impact of new drug development